Hypotrichosis: Clinical Trials

666 trials for Hypotrichosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

314 completed, 118 unknown, 75 recruiting, 47 not yet recruiting. 237 Not applicable, 171 Phase 2, 79 Phase 3, 75 Phase 1, 42 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable237Completed 108, Unknown 50, Recruiting 24, Active not recruiting 15, Not yet recruiting 14, Withdrawn 12, Terminated 10, Enrolling by invitation 4
Phase 2171Completed 87, Recruiting 19, Unknown 19, Not yet recruiting 13, Terminated 13, Withdrawn 10, Active not recruiting 9, Enrolling by invitation 1
Phase 379Completed 41, Recruiting 13, Not yet recruiting 8, Active not recruiting 7, Unknown 6, Terminated 2, Withdrawn 2
Phase 175Completed 32, Unknown 19, Recruiting 10, Terminated 5, Active not recruiting 3, Not yet recruiting 3, Withdrawn 2, Enrolling by invitation 1
Phase 442Completed 18, Unknown 12, Not yet recruiting 6, Recruiting 2, Terminated 2, Withdrawn 2
Early Phase 120Completed 10, Unknown 4, Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1

Follow Hypotrichosis: new trials by email Literature Review of Hypotrichosis trials Research Report on Hypotrichosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3Not yet recruitingEurofarma Laboratorios S.A.3722027-01-312026-11-06
Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss
DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness
Phase 3WithdrawnApplied Biology, Inc.2027-01-152026-11-02
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia
Minoxidil 5 %, Microneedling - Androgenetic Alopecia
Not applicableNot yet recruitingCheng Zhou1902027-01-012026-08-11
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3Not yet recruitingEurofarma Laboratorios S.A.3722027-01-012026-11-04
Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial
Platelet-Rich Plasma (PRP) Injections, Red-light photobiomodulation with cooling, Blue-light photobiomodulation - Androgenetic Alopecia
Early Phase 1Not yet recruitingKimberly Meathrel302026-12-302026-07-31
XVIE to Treat Androgenetic Alopecia (AGA)
Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution - Androgenetic Alopecia
Phase 1 / Phase 2Not yet recruitingRestore Biologics Holdings, Inc. dba Xtressé302026-12-012026-08-12
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial
Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia
Phase 2 / Phase 3Not yet recruitingSherief Ayman Hussein Shaamash402026-12-012026-10-07
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side - Androgenic Alopecia
Early Phase 1Not yet recruitingWake Forest University Health Sciences162026-12-012026-11-05
Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair
Xtressé Hair Growth Gummies, Placebo Comparator - Androgenetic Alopecia
Not applicableNot yet recruitingRestore Biologics Holdings, Inc. dba Xtressé302026-11-162026-11-05
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia
Phase 2Not yet recruitingPelage Pharmaceuticals, Inc.2002026-11-012026-11-06
Clinical Study to Evaluate the Impact of Nutraceutical Supplements in Participants With Self-Perceived Thinning Hair
Nutraceuticals (Prototype) - Hair Thinning
Not applicableNot yet recruitingUnilever R&D502026-10-082026-10-28
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
APSMNF 1, APSMNF 2, Eniagor® - Alopecia, Androgenetic
Phase 3Not yet recruitingApsen Farmaceutica S.A.3362026-10-072026-09-08
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
Dietary Supplement for Hair Loss - Alopecia
Not applicableNot yet recruitingFarmoquimica S.A.482026-10-012026-08-27
Oral Minoxidil With or Without a Multifactorial Drinkable Nutraceutical in Female Pattern Hair Loss: a Retrospective Study
Oral low-dose Minoxidil, Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women. - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Not yet recruitingOlistic Research Labs S.L.302026-10-012026-10-07
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women. - Gut Dysbiosis, Telogen Effluvium
Not yet recruitingOlistic Research Labs S.L.302026-10-012026-10-09
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata
Calcipotriol, Triamcinolone Acetonide - Alopecia Areata
Phase 4Not yet recruitingHayat Abad Medical Complex, Peshawar602026-10-012026-09-21
The Role of Gut and Skin Microbiota in Alopecia Areata
Fecal Microbial Transplant Enema, Placebo - Alopecia Areata, Fecal Microbiota Transplantation (FMT)
Not applicableNot yet recruitingPolyclinic GrandMed302026-10-012026-07-15
Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE)
Integrated Evidence-Based FUE Protocol, Standard FUE Practice - Androgenetic Alopecia, Cicatricial Alopecia
Not applicableNot yet recruitingAssiut University302026-10-012026-09-30
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast, Placebo (maltodextrin) - Androgenic Alopecia, Healthy Adult Male
Not applicableNot yet recruitingActiv'inside992026-09-302026-09-08
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
Xtressé Hair Growth Gummies, Placebo Comparator - Androgenic Alopecia, Hair Loss/Baldness
Not applicableEnrolling by invitationRestore Biologics Holdings, Inc. dba Xtressé482026-09-232026-10-27

Showing 20 of 666. Sign in to see all of them.

Narrower conditions

Alopecia (474)  ·  Alopecia Areata (219)  ·  Alopecia universalis (29)  ·  Dermatitis, Atopic (19)  ·  Psoriasis (19)  ·  Vitiligo (18)  ·  Breast Neoplasms (17)  ·  Hair Diseases (16)  ·  Hidradenitis Suppurativa (11)  ·  Skin Diseases (10)  ·  Acne Vulgaris (9)  ·  Autoimmune Diseases (8)  ·  Lichen Planus (8)  ·  Crohn Disease (7)

Broader conditions

Skin and Connective Tissue Diseases (666)  ·  Skin Diseases (656)  ·  Hair Diseases (650)  ·  Pathological Conditions, Signs and Symptoms (480)  ·  Pathological Conditions, Anatomical (473)  ·  Alopecia (183)  ·  Immune System Diseases (34)  ·  Neoplasms (32)  ·  Skin Diseases, Papulosquamous (31)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (29)  ·  Genetic Diseases, Inborn (28)  ·  Dermatitis (24)  ·  Neoplasms by Site (24)  ·  Skin Diseases, Eczematous (24)

Interventions

Minoxidil (54)  ·  Solutions (20)  ·  Triamcinolone Acetonide (17)  ·  Bimatoprost (13)  ·  Finasteride (13)  ·  Sodium Chloride (11)  ·  baricitinib (10)  ·  tofacitinib (9)  ·  Methotrexate (8)  ·  Saline Solution (8)  ·  Dutasteride (7)  ·  Dietary Supplements (6)  ·  Gels (5)  ·  Injections (5)  ·  Latanoprost (5)

Sponsors

Pfizer (17)  ·  Assiut University (16)  ·  University of Minnesota (12)  ·  Aderans Research Institute (11)  ·  Allergan (11)  ·  Applied Biology, Inc. (9)  ·  Sohag University (9)  ·  Suzhou Kintor Pharmaceutical Inc, (9)  ·  Cairo University (8)  ·  Kasr El Aini Hospital (8)  ·  Icahn School of Medicine at Mount Sinai (7)  ·  Ablon Skin Institute Research Center (6)  ·  Concert Pharmaceuticals (6)  ·  NovoBliss Research Pvt Ltd (6)  ·  Restore Biologics Holdings, Inc. dba Xtressé (6)

Countries

United States (284)  ·  China (54)  ·  Egypt (52)  ·  Canada (36)  ·  Spain (34)  ·  France (32)  ·  Germany (30)  ·  South Korea (30)  ·  Australia (26)  ·  Japan (22)  ·  Taiwan (22)  ·  United Kingdom (22)  ·  India (17)  ·  Poland (17)  ·  Brazil (15)

Top investigators

Maria Hordinsky, MD (10)  ·  Julian Mackay-Wiggan, MD, MS (6)  ·  Andy Goren, MD (4)  ·  Glynis Ablon, MD, FAAD (4)  ·  Kseniya Kobets, MD (4)  ·  Maria K Hordinsky, MD (4)  ·  Melissa Y Rayner, MS (4)  ·  Reid Waldman, M.D. (4)  ·  Timothy Durso, M.D. (4)  ·  Abe Marcadis, M.D. (3)  ·  Brett King, MD, PhD (3)

Results publications

PMID 38263353, PMID 41917311, PMID 42481842, PMID 25896390, PMID 27699252, PMID 28300084, PMID 28619556, PMID 29273099, PMID 35334197, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37917289, PMID 37991697, PMID 38904749, PMID 39962358, PMID 40214720, PMID 42823604, PMID 42825995, PMID 10327298, PMID 10495374, PMID 10583059, PMID 10677100, PMID 11511857, PMID 1188424, PMID 12789165, PMID 14582678, PMID 15034503, PMID 15577756, PMID 16417220, PMID 16616302, PMID 17196507, PMID 17236136, PMID 1739290, PMID 17557889, PMID 17569567, PMID 17637820, PMID 17761356, PMID 17785709, PMID 18329131, PMID 18489053, PMID 18645136, PMID 19061473, PMID 19277688, PMID 19293007, PMID 19366270, PMID 19620039, PMID 19909522, PMID 20115945

NIH funding

2025 (4), 2017 (3), 2023 (3), 2016 (2), 2009 (1), 2018 (1), P30CA013330 (1), R03CA088598 (1), R33AR077495 (1), R61AR084210 (1)